Localized and metastatic primary malignant bone sarcoma

Authored by Michael Wagner, published on 2026-05-28 00:58:41.0

The algorithm is broadly aligned with contemporary management of primary malignant bone sarcomas: referral to a sarcoma center, histology-driven pathways, multimodality therapy for osteosarcoma and Ewing sarcoma, and surgery-focused management for conventional chondrosarcoma. Key regimen choices (MAP for osteosarcoma; interval-compressed VDC/IE for Ewing) and emphasis on local control are consistent with major guideline recommendations and pivotal cooperative-group trials. Areas with more limited or evolving evidence include optimal systemic options for relapsed/metastatic osteosarcoma, the role of whole-lung irradiation in metastatic Ewing, and targeted/novel therapies in chondrosarcoma.

  1. Primary malignant bone sarcoma
    • Diagnostic workup (at sarcoma center)
      Biopsy MRI (primary site) CT chest (± contrast) ± PET/CT or bone scan as indicated
      • Histology + Grade + Resectability + Metastatic Status
        • Osteosarcoma
          Most common in children, adolescents, and young adults. Conventional high-grade is chemo-sensitive.
          • Localized Disease
            • Neoadjuvant MAP Chemotherapy
              MAP: Methotrexate Adriamycin (the brand name for doxorubicin) Platinum (the common nickname for cisplatin)
              • Surgical Resection
                Limb-sparing surgery when feasible (amputation if necessary)
                • Adjuvant MAP Chemotherapy
                  MAP to complete planned course (typically ~6 months total)
          • Metastatic / Recurrent disease
            • Systemic Chemotherapy
              MAP or appropriate regimen for recurrence MAP: Methotrexate Adriamycin (the brand name for doxorubicin) Platinum (the common nickname for cisplatin)
              • Pulmonary metastasectomy when feasible
                • Consider Clinical Trials
                  for recurrent / refractory disease
        • Ewing sarcoma
          Most common in children, adolescents, and young adults. Highly chemo-sensitive.
          • Localized Disease
            • Systemic Chemotherapy (Interval-compressed VDC/IE)
              The VDC Cycle (VDC stands for the combination of the following three drugs): Vincristine Doxorubicin Cyclophosphamide The IE Cycle (IE stands for the combination of these two drugs): Ifosfamide Etoposide
              • Local Control (Surgery ± RT)
                Surgery (preferred when feasible) AND/OR Radiation Therapy
                • Continuation VDC/IE
                  Continue VDC/IE to complete planned course (typically ~14 cycles / 14–17 mo)
          • Metastatic / Recurrent disease
            • Systemic Chemotherapy (Interval-compressed VDC/IE)
              The VDC Cycle (VDC stands for the combination of the following three drugs): Vincristine Doxorubicin Cyclophosphamide The IE Cycle (IE stands for the combination of these two drugs): Ifosfamide Etoposide
              • Local Control (Surgery ± RT)
                To primary site and metastatic sites as indicated (surgery and/or RT) Consider whole-lung radiation therapy. May be used for select patients with pulmonary metastases.
                • Consider Clinical Trials
                  for relapsed / refractory disease
        • Chondrosarcoma
          Most common in adults. Conventional type is generally not chemo-sensitive.
          • Localized Disease
            • Wide Surgical Resection
              Wide en bloc resection with negative margins
              • Selective RT use (skull base/spine/unresectable disease)
                Considered in select cases (e.g., skull base, spine, or when margins close/positive)
          • Metastatic / Recurrent disease
            • Surgical resection when feasible
              of primary when feasible
              • Limited systemic therapy options
                Limited efficacy
              • Clinical trial / targeted therapy consideration
              • Mesenchymal/dedifferentiated variants may receive sarcoma-type chemotherapy
                Mesenchymal or dedifferentiated chondrosarcoma may be treated with systemic therapy (e.g., osteosarcoma-like regimens)
  2. Multidisciplinary evaluation at a high-volume sarcoma center is recommended for all patients with sarcoma
tosprivacy